Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2026)

Neuroone Medical Technologies (NMTC) has 10 years of Cash & Equivalents data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 112.38% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 112.38% YoY), and the FY2025 full-year result was $6.6 million, up 350.01% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.8 million, down from $3.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.9 million in Q1 2022 and bottomed at $1.1 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $3.6 million (2025), against an average of $4.7 million.
• The widest annual swing landed in 2024, when Cash & Equivalents plunged 72.57%; it then soared 396.28% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $4.7 million in 2022, then slumped by 42.56% to $2.7 million in 2023, then sank by 57.69% to $1.1 million in 2024, then jumped by 217.36% to $3.6 million in 2025, then retreated by 22.11% to $2.8 million in 2026.
• The last three Cash & Equivalents figures came in at $2.8 million (Q1 2026), $3.6 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.

Peer Comparison